Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Buy Rating for Arcturus Therapeutics: Advancing Clinical Programs and Strengthening Safety Profile
Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Arcturus Therapeutics Analyst Ratings
Buy Rating Affirmed: Promising Developments in Arcturus Therapeutics' MRNA Treatments for Rare Diseases
Piper Sandler Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), Corcept Therapeutics (CORT) and Arcturus Therapeutics (ARCT)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM), Arcturus Therapeutics (ARCT) and Johnson & Johnson (JNJ)
Arcturus Therapeutics Analyst Ratings
Buy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical Advancements
Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan
Arcturus Therapeutics Analyst Ratings
Arcturus Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating
Arcturus Therapeutics Analyst Ratings
Arcturus Therapeutics (ARCT) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT)
Arcturus Therapeutics Analyst Ratings